πŸ‡ΊπŸ‡Έ FDA
Patent

US 11421231

Modulation of Huntington expression

granted A61PA61P1/00A61P15/00

Quick answer

US patent 11421231 (Modulation of Huntington expression) held by Ionis Pharmaceuticals, Inc. expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P1/00, A61P15/00, A61P19/10, A61P21/02